Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, B Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS.

Ann Neurol. 2013 Jul;74(1):119-27. doi: 10.1002/ana.23872. Epub 2013 Aug 6.

2.

Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.

Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS.

Mov Disord. 2015 Oct;30(12):1648-56. doi: 10.1002/mds.26290. Epub 2015 Jul 24.

3.

Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype.

Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS.

Mov Disord. 2015 May;30(6):805-12. doi: 10.1002/mds.26022. Epub 2014 Sep 16.

4.

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators..

Neurology. 2014 Nov 4;83(19):1739-46. doi: 10.1212/WNL.0000000000000960. Epub 2014 Oct 8.

5.

Uric acid relates to dopamine transporter availability in Parkinson's disease.

Moccia M, Pappatà S, Erro R, Picillo M, Vitale C, Amboni M, Longo K, Palladino R, Barone P, Pellecchia MT.

Acta Neurol Scand. 2015 Feb;131(2):127-31. doi: 10.1111/ane.12295. Epub 2014 Oct 7.

PMID:
25288358
6.

Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.

Erro R, Pappatà S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P.

Parkinsonism Relat Disord. 2012 Nov;18(9):1034-8. doi: 10.1016/j.parkreldis.2012.05.022. Epub 2012 Jul 11.

PMID:
22789824
7.

Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, Borghammer P, Brooks DJ, Pavese N.

Brain. 2015 Oct;138(Pt 10):2964-73. doi: 10.1093/brain/awv215. Epub 2015 Jul 23.

PMID:
26209314
8.
9.

Genome-wide variant by serum urate interaction in Parkinson's disease.

Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN.

Ann Neurol. 2015 Nov;78(5):731-41. doi: 10.1002/ana.24504. Epub 2015 Aug 29.

PMID:
26284320
10.

Does education modify motor compensation in Parkinson's disease?

Sunwoo MK, Hong JY, Lee JJ, Lee PH, Sohn YH.

J Neurol Sci. 2016 Mar 15;362:118-20. doi: 10.1016/j.jns.2016.01.030. Epub 2016 Jan 24.

PMID:
26944130
11.

Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.

Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappatà S.

Parkinsonism Relat Disord. 2015 May;21(5):489-93. doi: 10.1016/j.parkreldis.2015.02.015. Epub 2015 Feb 25.

PMID:
25753457
12.

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.

van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD.

Eur J Neurol. 2014 Mar;21(3):388-94. doi: 10.1111/ene.12176. Epub 2013 Apr 30.

PMID:
23631635
13.

Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.

Bor-Seng-Shu E, Pedroso JL, Felicio AC, de Andrade DC, Teixeira MJ, Braga-Neto P, Batista IR, Barsottini OG, Borges V, Ferraz HB, Shih MC, Bressan RA, de Andrade LA, Walter U.

Parkinsonism Relat Disord. 2014 May;20(5):477-81. doi: 10.1016/j.parkreldis.2014.01.015. Epub 2014 Feb 6.

PMID:
24629800
15.

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators..

Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29.

16.

Higher dopamine transporter density in Parkinson's disease patients with depression.

Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, Silva SM, Amaro-Junior E, Andrade LA, Ferraz HB, Bressan RA.

Psychopharmacology (Berl). 2010 Jul;211(1):27-31. doi: 10.1007/s00213-010-1867-y. Epub 2010 May 22.

PMID:
20495790
17.

Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.

Nocker M, Seppi K, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1012-20. doi: 10.1007/s00259-012-2100-5. Epub 2012 Mar 30.

PMID:
22460689
18.

Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels.

Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, Harrison N, Vivian G, Ray Chaudhuri K.

J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):148-52. doi: 10.1136/jnnp-2013-305395. Epub 2013 Jul 30.

19.

Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.

Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D.

Neuroimage. 2004 Apr;21(4):1497-507.

PMID:
15050574
20.

Parkinson's disease and dopamine transporter neuroimaging: a critical review.

Shih MC, Hoexter MQ, Andrade LA, Bressan RA.

Sao Paulo Med J. 2006 May 4;124(3):168-75. Review.

Supplemental Content

Support Center